Drug Profile
MTL 001
Alternative Names: MTL-001Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Morvus Technology
- Class Antiparasitics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Leishmaniasis; Trypanosomiasis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Leishmaniasis in United Kingdom (unspecified route)
- 05 Sep 2023 Discontinued - Preclinical for Trypanosomiasis in United Kingdom (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Leishmaniasis in United Kingdom